Related Experiment Video
Updated: Feb 16, 2026
Cerenkov Luminescence Imaging CLI for Cancer Therapy Monitoring
Published on: November 13, 2012
Cancer terminator viruses (CTV): A better solution for viral-based therapy of cancer
Luni Emdad1, Swadesh K Das1, Xiang-Yang Wang1
1Department of Human and Molecular Genetics, School of Medicine, VCU Institute of Molecular Medicine and VCU Massey Cancer Center, Virginia Commonwealth University, Richmond, Virginia.
Abstract:
In principle, viral gene therapy holds significant potential for the therapy of solid cancers. However, this promise has not been fully realized and systemic administration of viruses has not proven as successful as envisioned in the clinical arena. Our research is focused on developing the next generation of efficacious viruses to specifically treat both primary cancers and a major cause of cancer lethality, metastatic tumors (that have spread from a primary site of origin to other areas in the body and are responsible for an estimated 90% of cancer deaths). We have generated a chimeric tropism-modified type 5 and 3 adenovirus that selectively replicates in cancer cells and simultaneously produces a secreted anti-cancer toxic cytokine, melanoma differentiation associated gene-7/Interleukin-24 (mda-7/IL-24), referred to as a Cancer Terminator Virus (CTV) (Ad.5/3-CTV). In preclinical animal models, injection into a primary tumor causes selective cell death and therapeutic activity is also observed in non-injected distant tumors, that is, "bystander anti-tumor activity." To enhance the impact and therapeutic utility of the CTV, we have pioneered an elegant approach in which viruses are encapsulated in microbubbles allowing "stealth delivery" to tumor cells that when treated with focused ultrasound causes viral release killing tumor cells through viral replication, and producing and secreting MDA-7/IL-24, which stimulates the immune system to attack distant cancers, inhibits tumor angiogenesis and directly promotes apoptosis in distant cancer cells. This strategy is called UTMD (ultrasound-targeted microbubble-destruction). This novel CTV and UTMD approach hold significant promise for the effective therapy of primary and disseminated tumors.
Insights
This study introduces a novel Cancer Terminator Virus (CTV) for treating primary and metastatic tumors. Ultrasound-targeted microbubble-destruction (UTMD) enhances viral delivery and anti-cancer effects, showing promise for solid cancer therapy.
Area of Science:
- Oncolytic virotherapy
- Gene therapy
- Cancer research
Background:
- Viral gene therapy for solid cancers shows potential but faces challenges with systemic administration.
- Metastatic tumors are a major cause of cancer mortality, necessitating advanced therapeutic strategies.
- Current approaches often lack specificity and efficacy against disseminated disease.
Purpose of the Study:
- To develop an enhanced viral therapy for primary and metastatic solid tumors.
- To engineer a virus that selectively replicates in cancer cells and delivers anti-cancer agents.
- To improve viral delivery and therapeutic impact using a novel targeted approach.
Main Methods:
- Generation of a chimeric tropism-modified adenovirus (Ad.5/3-CTV) engineered to selectively replicate in cancer cells and produce melanoma differentiation associated gene-7/Interleukin-24 (mda-7/IL-24).
- Encapsulation of the Cancer Terminator Virus (CTV) in microbubbles for stealth delivery.
- Application of focused ultrasound to trigger microbubble destruction and targeted viral release (ultrasound-targeted microbubble-destruction, UTMD).
Main Results:
- Preclinical models demonstrated selective cancer cell death upon primary tumor injection.
- Observed bystander anti-tumor activity in non-injected distant tumors.
- UTMD approach enhanced viral delivery, leading to tumor cell death, cytokine secretion, immune stimulation, and inhibition of angiogenesis and apoptosis in distant cancers.
Conclusions:
- The novel Cancer Terminator Virus (CTV) demonstrates selective replication and potent anti-tumor activity.
- Ultrasound-targeted microbubble-destruction (UTMD) significantly enhances the therapeutic efficacy of CTV for primary and disseminated tumors.
- This combined approach offers a promising strategy for overcoming limitations in current cancer gene therapy.
More Related Videos
19:02High-Efficiency Transduction of Liver Cancer Cells by Recombinant Adeno-Associated Virus Serotype 3 Vectors
Published on: March 22, 2011
07:55Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer
Published on: January 17, 2025
Related Concept Videos
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:03Rous Sarcoma Virus (RSV) and Cancer
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
03:21Weak Base Solutions
02:18Cancer
02:12What is Cancer?
Although people have known about cancer for centuries, it was only in 1761 that Giovanni Morgagni of Padua performed a detailed autopsy of...